Drug Shortage Report for ANGIOMAX
| Report ID | 279966 |
| Drug Identification Number | 02246533 |
| Brand name | ANGIOMAX |
| Common or Proper name | ANGIOMAX |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | BIVALIRUDIN |
| Strength(s) | 250MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10LYVI |
| ATC code | B01AE |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2026-03-09 |
| Estimated end date | Unknown |
| Actual end date | 2026-03-16 |
| Shortage status | Actual shortage |
| Updated date | 2026-03-16 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 4600 RUE ARMAND-FRAPPIER SAINT-HUBERT, QUEBEC CANADA J3Z 1G5 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2026-03-16 | French | Compare |
| v3 | 2026-03-16 | English | Compare |
| v2 | 2026-03-09 | French | Compare |
| v1 | 2026-03-09 | English | Compare |
Showing 1 to 4 of 4